Drug intelligence / Profile preview

danshen (salvia) injection

Development stage: Unknown
Lead developer: ChiaTai Qingchunbao Pharmaceutical
Administration: Intravenous, Intramuscular, Parenteral

Targets

OAT1/OAT3 (Solute carrier family 22 member 6 (OAT1) and Solute carrier family 22 member 8 (OAT3))P2RY1 (Purinergic Receptor P2Y1)IL-6 (Interleukin 6)MMP9 (Matrix metalloproteinase-9)ABCB1 (P-glycoprotein)VEGFA (Vascular endothelial growth factor A)NOS3 (eNOS)P2Y12 (Purinergic P2Y12 receptor)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)Cyp (Cyclophilin family)

Beyond the preview

Go deeper on danshen (salvia) injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on danshen (salvia) injection.

Explore the full profile